Ind-Swift Laboratories Ltd. (INDSWFTLAB) AI Stock Analysis

Ind-Swift Laboratories Ltd.

(NSE:INDSWFTLAB)

Select Model

Rating:57Neutral

Price Target:INR 380.00▲(7.28% Upside)

Action:reiterated

Date:10/31/26

The overall score of 57 reflects a company with a fortress-like balance sheet but significant operational headwinds. The primary strength is financial stability from minimal debt, while the biggest risks are the persistent negative cash flows and declining profitability, which make the high P/E valuation difficult to justify. Neutral technicals provide little offsetting catalyst.

Positive Factors

Stronger balance sheetMeaningfully lower leverage and a steadily expanding equity base improve the company’s financial resilience. This provides greater flexibility to support pharmaceutical manufacturing operations, absorb business volatility, and pursue growth without the same dependence on debt financing.

Negative Factors

Recent revenue contractionThe repeated decline in revenue indicates weakened operating momentum rather than a single isolated fluctuation. Sustained top-line contraction can reduce capacity utilization, limit operating leverage, and make it harder for the company to maintain profitability across its API and intermediate portfolio.

Ind-Swift Laboratories Ltd. (INDSWFTLAB) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 34.45B
Dividend Yield: ―
Average Volume (3M): 71.99K
Price to Earnings (P/E): 36.2
Beta (1Y): 0.82
Revenue Growth: 66.39%
EPS Growth: -72.31%
Country: India
Employees: 1,388
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Ind-Swift Laboratories Ltd. Business Overview & Revenue Model

Company Description

Ind-Swift Laboratories Limited, an Indian enterprise, is engaged in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's comprehensive API portfolio addresses numerous therapeutic domains, including...

How the Company Makes Money

The company primarily makes money by producing and selling active pharmaceutical ingredients (APIs) and pharmaceutical intermediates to other pharmaceutical companies that use these inputs to manufacture finished formulations (tablets, capsules, inje...

Ind-Swift Laboratories Ltd. Financial Statement Overview

Summary

Financial performance is mixed. The balance sheet is a major strength with negligible debt and high equity (Score 85). However, the income statement shows declining revenue and compressed margins (Score 55), and cash flows have been negative for three years (Score 30). The weighted average of these sub-scores, prioritizing the cash flow weakness, results in a below-average overall financial score.

Income Statement

55Neutral

Balance Sheet

85Very Positive

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Jun 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	6.65B	6.41B	5.62B	12.81B	12.07B	10.39B
Gross Profit	2.44B	1.90B	2.74B	4.13B	4.40B	4.10B
EBITDA	772.79M	450.97M	2.85B	7.82B	2.36B	2.35B
Net Income	573.25M	414.15M	2.50B	4.21B	475.97M	-21.49M
Balance Sheet
Total Assets	0	16.73B	14.38B	14.60B	18.24B	18.01B
Cash, Cash Equivalents and Short-Term Investments	4.42B	4.72B	4.82B	4.94B	231.54M	333.68M
Total Debt	0	205.01M	408.41M	166.22M	8.62B	9.53B
Total Liabilities	-13.84B	2.89B	2.65B	6.48B	11.42B	12.00B
Stockholders Equity	13.84B	13.84B	11.73B	9.36B	6.82B	6.01B
Cash Flow
Free Cash Flow	-472.94M	-1.08B	-898.80M	-2.08B	1.82B	1.32B
Operating Cash Flow	-202.50M	-198.64M	-254.74M	-1.63B	1.95B	1.50B
Investing Cash Flow	-1.04B	-1.28B	-1.10B	-1.23B	-133.68M	47.72M
Financing Cash Flow	961.18M	1.47B	692.05M	6.99B	-1.86B	-1.41B

Ind-Swift Laboratories Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price354.20

Price Trends

50DMA370.61Negative

100DMA298.17Positive

200DMA216.26Positive

Market Momentum

MACD-0.60Negative

RSI46.90Neutral

STOCH53.57Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDSWFTLAB, the sentiment is Negative. The current price of 354.20 is below the 20-day moving average (MA) of 364.89, below the 50-day MA of 370.61, and above the 200-day MA of 216.26, indicating a neutral trend. The MACD of -0.60 indicates Negative momentum. The RSI at 46.90 is Neutral, neither overbought nor oversold. The STOCH value of 53.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:INDSWFTLAB.

Ind-Swift Laboratories Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:INDSWFTLAB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:VENUSREM	69Neutral	INR 16.46B	14.28	―	0.78%	20.22%	73.03%
IN:LINCOLN	67Neutral	INR 10.05B	10.63	―	0.35%	10.20%	11.70%
IN:INDSWFTLAB	57Neutral	INR 31.95B	36.19	―	―	66.39%	-72.31%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:SOLARA	51Neutral	INR 30.43B	82.27	―	―	27.30%	456.80%
IN:INDOCO	50Neutral	INR 19.23B	63.42	―	0.09%	10.75%	―
IN:HIKAL	47Neutral	INR 26.01B	-80.56	―	0.27%	-5.37%	-153.40%

* General Sector Average

Performance Comparison

IN:INDSWFTLAB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:INDSWFTLAB	Ind-Swift Laboratories Ltd.	354.20	252.40	247.94%
IN:HIKAL	Hikal Limited	220.65	-19.12	-7.98%
IN:INDOCO	Indoco Remedies Limited	215.85	-57.11	-20.92%
IN:LINCOLN	Lincoln Pharmaceuticals Ltd	511.95	-12.31	-2.35%
IN:SOLARA	Solara Active Pharma Sciences Ltd.	636.70	19.30	3.13%
IN:VENUSREM	Venus Remedies Limited	1293.30	852.84	193.62%

Ind-Swift Laboratories Ltd. Corporate Events

Ind-Swift Laboratories schedules virtual investor meet with Arihant Capital

Sep 23, 2026

Ind-Swift Laboratories Ltd. has scheduled a virtual group meeting with Arihant Capital on September 29, 2026, as part of its ongoing engagement with analysts and institutional investors under SEBI’s listing obligations framework. The company em...

Ind-Swift Laboratories Publishes Notices for 31st AGM and Annual Report Access

Sep 6, 2026

Ind-Swift Laboratories Ltd., a listed Indian pharmaceutical company, manufactures and markets healthcare and drug products for a range of domestic and international customers. The company’s shares trade on BSE and NSE, positioning it within the...

Ind-Swift Laboratories Sets Q1 FY27 Earnings Call for August 17

Aug 12, 2026

Ind-Swift Laboratories Ltd. has scheduled an earnings conference call to discuss its financial results for the quarter ended June 30, 2026. The call will be held on Monday, August 17, 2026, at 3:00 p.m. IST and will feature senior finance and corpora...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026

Ind-Swift Laboratories Ltd. AI Stock Analysis